research conducted by our founders at VRISD and VCU. VLP's principle technology is a vaccine carrier platform based on the highly immunogenic hepatitis virus core protein. This virus...-like particle technology represents a major advancement in medicine because it generates higher levels of therapeutic antibodies compared to conventional vaccines and thus elicits... stronger immune responses. This allows us to achieve successful clinical outcomes with fewer immunizations than those required by other prophylactic vaccines and has the potential...

at Merck he was responsible for world wide clinical development and licensure of novel vaccines/vaccine combinations as well as the clinical assessment of vaccine targets. Robert Blatt... of Vice President-Business Development at Torrey Pines Bank. David Milich, Ph.D. (Director, Founder and CEO): Dr. Milich is a world-renowned immunologist with extensive experience... asset for VLP's clinical development programs. Dr. Milich is also President and CEO of VRISD. Prior to starting VLP Biotech, Dr. Milich also co-founded Immune Complex Corporation...

candidate is a malaria vaccine which is based on the neutralizing circumsporozite repeat sequence known to be protective against malaria. Studies with this vaccine reiterate our carrier's... candidate is an M2-based human influenza vaccine that offers long-term protection against all type A flu strains, eliminating the need for annual immunizations. Preliminary studies have... already demonstrated protection in animal models. Pre-clinical development continues with the intent to begin a Phase I clinical trial in early 2010. HCV A panel of VLPs in pre...